OncoSynergy, a South San Francisco, CA-based oncology therapeutics spinout from UCSF, closed a Series A equity funding round.
The round was led by Connecticut Innovations (CI) with participation from current shareholders NLabs, Inc., and Korea Information & Communication Co., Ltd.
The company intends to use the funds to accelerate their lead program, OS2966, to the clinic for the treatment of glioblastoma, the most common and deadliest primary brain tumor in adults.
Led by W. Shawn Carbonell, MD, PhD, Founder and CEO, OncoSynergy has developed a new class of oncology therapeutics called Resistance Mechanism Inhibitors (RMIs). RMIs feature multiple simultaneous mechanisms of action, synergy in combination with other treatments, including immunotherapies in preclinical models, and can potentially be used to treat many types of solid and hematological cancers.
The FDA has granted two Orphan Drug Designations for OS2966, the lead RMI program, including in the treatment of glioblastoma.
The planned clinical trial is a strategic alliance with Infuseon Therapeutics, a medical device spinout of the Cleveland Clinic.
OncoSynergy will be relocating its headquarters to Connecticut and expanding its team in anticipation of its first clinical trial in 2019.